FDA-Approved GLP-1 Drugs for Weight Loss in 2026

The FDA has now approved five GLP-1 medications specifically for chronic weight management — three injectable, two oral. Every other GLP-1 used for weight loss (Ozempic, Mounjaro) is being prescribed off-label — which is legal but doesn't qualify for weight-management-specific savings programs.

The official approved list for weight loss, as of 2026:

FDA-approved GLP-1 medications for weight management

The eligibility criteria on all five are the same:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, etc.)

Each drug has its own dosing, side-effect profile and average trial results.

Saxenda (liraglutide)

The first GLP-1 ever approved for weight management.

• Approved (weight): 2014
• Maker: Novo Nordisk
• Form: Daily subcutaneous injection
• Dose range: 0.6 → 3.0 mg/day (weekly titration)
• Trial weight loss: ~8% body weight at 56 weeks (SCALE trial)
• Cash-pay: ~$1,349/month list

Pros: Long track record; daily injection has a shorter half-life if you want to stop quickly. Cons: Daily dosing is an adherence burden; lower average weight loss than newer weekly options.

Wegovy (semaglutide)

The breakthrough that made GLP-1 weight loss mainstream.

• Approved (weight): 2021
• Maker: Novo Nordisk
• Form: Weekly subcutaneous injection
• Dose range: 0.25 → 2.4 mg/week, plus Wegovy HD 7.2 mg
• Trial weight loss: ~15% body weight at 68 weeks (STEP-1)
• Cash-pay: ~$1,349/month list; $349/month via NovoCare direct
• Additional approvals: Cardiovascular risk reduction (SELECT, 2024); MASH with moderate-to-advanced fibrosis (2024–2025)

Strongest cardiovascular evidence in the class. Now also approved for MASH (metabolic-associated steatohepatitis).

Zepbound (tirzepatide)

The current weight-loss leader by trial average.

• Approved (weight): 2023
• Maker: Eli Lilly
• Form: Weekly subcutaneous injection (pens, KwikPen, LillyDirect vials)
• Dose range: 2.5 → 15 mg/week
• Trial weight loss: ~21% body weight at 72 weeks (SURMOUNT-1)
• Cash-pay: ~$1,299/month (pens); $349–$499/month via LillyDirect vials
• Additional approvals: Moderate-to-severe obstructive sleep apnea in adults with obesity (2024)

The dual GLP-1 / GIP agonist mechanism is what makes tirzepatide outperform single-receptor semaglutide on average weight loss.

Wegovy oral (semaglutide pill)

Same active molecule as injectable Wegovy, in a pill.

• Approved: December 2025
• Maker: Novo Nordisk
• Form: Daily oral tablet
• Dose range: 0.25 → 25 mg/day (much higher than injection because of poor oral bioavailability)
• Trial weight loss: ~13% body weight at 64 weeks (OASIS program)
• Cash-pay: $149/month for 1.5 mg and 4 mg (intro pricing through Aug 2026, then $199); $199/month for 0.25 / 0.5 mg start doses
• How to take it: Empty stomach, first thing in the morning, 30 minutes before any food, drink (except water), or other medication

The empty-stomach requirement is a real adherence challenge for people already taking medications like levothyroxine or omeprazole.

Foundayo (orforglipron)

The first oral small-molecule GLP-1 — easier to take than oral Wegovy.

• Approved: 2026 (under FDA National Priority Voucher program)
• Maker: Eli Lilly
• Form: Daily oral tablet
• Dose range: 0.8 → 17.2 mg/day (six strengths)
• Trial weight loss: ~12% body weight at the highest dose; ~27 lb average vs ~2 lb placebo in 72-week trial
• Cash-pay: From $149/month via LillyDirect
• Insurance options: ~$25/month with commercial insurance + Lilly discount card; ~$50/month with Medicare Part D starting July 2026

Foundayo's edge: it can be taken any time of day, with or without food — unlike oral Wegovy. The trade-off is somewhat lower average weight loss than the injectables.

What's NOT FDA-approved for weight loss (but commonly used off-label)

These GLP-1 drugs are FDA-approved for type 2 diabetes, not weight loss. Doctors can prescribe them off-label for weight loss, and many do, but:

• They don't qualify for weight-loss-specific savings programs
• Insurance generally won't cover them for off-label weight loss
• The cash-pay price applies in full

The big off-label ones:

• Ozempic (semaglutide, weekly injection) — approved for T2D, not weight management
• Mounjaro (tirzepatide, weekly injection) — approved for T2D, not weight management
• Rybelsus (semaglutide, daily oral 3-14 mg) — approved for T2D
• Trulicity (dulaglutide, weekly injection) — approved for T2D
• Victoza (liraglutide, daily injection) — approved for T2D
• Byetta / Bydureon (exenatide) — approved for T2D

For the full picture, see GLP-1 drugs list.

Pipeline: drugs heading for weight-management approval

• Retatrutide (Eli Lilly) — triple agonist GLP-1/GIP/glucagon. Phase 3 TRIUMPH program reading through 2026; NDA expected late 2026; weight-management approval projected 2027–2028. Phase 2 results showed ~24% weight loss. See our Retatrutide guide.
• Survodutide (Boehringer Ingelheim / Zealand) — dual GLP-1/glucagon agonist; Phase 3 for obesity and MASH
• CagriSema (Novo Nordisk) — combination of cagrilintide + semaglutide; Phase 3 read-outs 2026
• Pemvidutide (Altimmune) — dual GLP-1/glucagon; clinical development for obesity and MASH

How to choose among FDA-approved weight-loss GLP-1s

1. Coverage: What does your insurance cover for weight management?
2. Dosing preference: Injection (weekly preferred for adherence) or pill (Foundayo > oral Wegovy on convenience)
3. Comorbidities: Heart disease → Wegovy (SELECT CV outcomes data). OSA → Zepbound (OSA approval).
4. Cost: Manufacturer programs differ by drug. See GLP-1 cost.

For the head-to-head ranking by efficacy, see best GLP-1 for weight loss.

FAQ

Is Ozempic FDA-approved for weight loss? No. Ozempic is FDA-approved for type 2 diabetes. It's commonly prescribed off-label for weight loss but the weight-loss indication belongs to Wegovy (the higher-dose semaglutide brand).

Is Mounjaro FDA-approved for weight loss? No. Mounjaro is FDA-approved for type 2 diabetes. The weight-management brand of tirzepatide is Zepbound.

What's the newest FDA-approved GLP-1 for weight loss? Foundayo (orforglipron), approved in 2026. Before that, oral Wegovy in December 2025.

Will my insurance cover an FDA-approved weight-loss GLP-1? Coverage varies. Many employer plans now cover Wegovy or Zepbound for patients meeting BMI criteria; coverage requires prior authorization in most cases.

When will retatrutide be FDA-approved? Projected late 2027 to early 2028 if Phase 3 trials read out as expected and the FDA review proceeds on standard timelines.

---

This article is for educational purposes only and is not medical advice. FDA approvals and indications change. Verify current FDA-approved indications and labeling at the relevant FDA drug page or with a qualified healthcare professional.